Neogenomics (NEO) EBT (2010 - 2026)

Neogenomics has reported EBT for 17 years, with the latest figure at -$17.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 31.49% year-over-year to -$17.6 million; the trailing twelve-month figure through Mar 2026 stood at -$102.2 million (down 29.93% YoY), and the FY2025 full-year result was -$110.3 million, down 36.68% from the prior year.
• EBT for Q1 2026 stood at -$17.6 million, down from -$12.4 million in the prior quarter.
• The five-year high for EBT was -$12.4 million in Q4 2025, with the low at -$53.2 million in Q1 2022.
• Historically, EBT has averaged -$27.4 million across 5 years, with a median of -$25.7 million in 2025.
• Annual changes were most pronounced in 2022 — EBT plunged 155.88% — and 2023, when it soared 45.86%.
• Neogenomics' EBT stood at -$25.5 million in 2022, then soared by 40.11% to -$15.3 million in 2023, then fell by 5.51% to -$16.1 million in 2024, then climbed by 23.08% to -$12.4 million in 2025, then sank by 41.69% to -$17.6 million in 2026.
• The last three EBT figures came in at -$17.6 million (Q1 2026), -$12.4 million (Q4 2025), and -$26.4 million (Q3 2025), per Business Quant data.